Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Insulet Corporation
In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.
Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.
Private Company Edition: Perceptive/Xontogeny, Abingworth, Kizoo and Droia closed venture capital funds. New biopharma VC financings also include a $105m series C round for Elpiscience and $92m for newly launched Interline.
Unmet needs are at the core of Endeavour Vision’s investment strategy, accepting that payment models may need to change as patients become more directly involved in device development.
- Medical Devices
- Other Names / Subsidiaries
- Insulet Canada Corporation
- Neighborhood Diabetes
- Neighborhood Holdings, Inc.